Alpha-synuclein kinase

US8148089B2 · kind B2 · utility

Assignee

• Elan Pharma International Ltd. · IE

Inventors

• John P. Anderson · Langenfeld, DE
• Kelly Banducci · Pleasanton, US
• Guriqbal Basi · Palo Alto, US
• David Chereau · San Mateo, US
• Tamie J. Chilcote · San Francisco, US
• Normand Frigon · Pleasant Hill, US
• Jason Goldstein · Burlingame, US
• Irene Griswold · San Francisco, US

Key dates

• Filing date: Feb 8, 2010
• Grant date: Apr 3, 2012
• Expiry date: Jul 25, 2030

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/28
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.